Biomarin Pharmaceutical Inc [BMRN] stock is trading at $57.28, up 0.21%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The BMRN shares have gain 3.64% over the last week, with a monthly amount drifted -4.18%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Biomarin Pharmaceutical Inc [NASDAQ: BMRN] stock has seen the most recent analyst activity on February 24, 2025, when Oppenheimer upgraded its rating to a Outperform but kept the price target unchanged to $98 for it. Previously, Wolfe Research started tracking the stock with Outperform rating on November 15, 2024, and set its price target to $95. On October 30, 2024, downgrade downgraded it’s rating to Mkt Perform. Bernstein upgraded its rating to a Outperform and raised its price target to $110 on August 20, 2024. Robert W. Baird downgraded its rating to Neutral for this stock on May 17, 2024, and downed its price target to $72. In a note dated May 14, 2024, Evercore ISI initiated an Outperform rating and provided a target price of $113 on this stock.
Biomarin Pharmaceutical Inc [BMRN] stock has fluctuated between $52.93 and $94.85 over the past year. Currently, Wall Street analysts expect the stock to reach $101.7 within the next 12 months. Biomarin Pharmaceutical Inc [NASDAQ: BMRN] shares were valued at $57.28 at the most recent close of the market. An investor can expect a potential return of 77.55% based on the average BMRN price forecast.
Analyzing the BMRN fundamentals
Biomarin Pharmaceutical Inc [NASDAQ:BMRN] reported sales of 2.92B for the trailing twelve months, which represents a growth of 12.72%. Gross Profit Margin for this corporation currently stands at 0.79% with Operating Profit Margin at 0.21%, Pretax Profit Margin comes in at 0.23%, and Net Profit Margin reading is 0.18%. To continue investigating profitability, this company’s Return on Assets is posted at 0.07, Equity is 0.09 and Total Capital is 0.09. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.1.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
For context, Biomarin Pharmaceutical Inc’s Current Ratio is 5.52. As well, the Quick Ratio is 3.49, while the Cash Ratio is 1.67. Considering the valuation of this stock, the price to sales ratio is 3.76, the price to book ratio is 1.90 and price to earnings (TTM) ratio is 21.25.
Transactions by insiders
Recent insider trading involved Burkhart Erin, GVP, Chief Accounting Officer, that happened on May 20 ’25 when 1786.0 shares were sold. Officer, Burkhart Erin completed a deal on May 20 ’25 to buy 1786.0 shares. Meanwhile, EVP, Chief Commercial Officer Hubbard Cristin sold 273.0 shares on May 02 ’25.
